DE60114018D1 - Von zellen präsentierte peptide - Google Patents

Von zellen präsentierte peptide

Info

Publication number
DE60114018D1
DE60114018D1 DE60114018T DE60114018T DE60114018D1 DE 60114018 D1 DE60114018 D1 DE 60114018D1 DE 60114018 T DE60114018 T DE 60114018T DE 60114018 T DE60114018 T DE 60114018T DE 60114018 D1 DE60114018 D1 DE 60114018D1
Authority
DE
Germany
Prior art keywords
peptides
determination
relates
present
presented peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60114018T
Other languages
English (en)
Other versions
DE60114018T2 (de
Inventor
J Carr
Graham Carter
Koen Hellendoorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of DE60114018D1 publication Critical patent/DE60114018D1/de
Application granted granted Critical
Publication of DE60114018T2 publication Critical patent/DE60114018T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60114018T 2000-08-03 2001-07-26 Von zellen präsentierte peptide Expired - Lifetime DE60114018T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0018901.9A GB0018901D0 (en) 2000-08-03 2000-08-03 Peptides presented by cells
GB0018901 2000-08-03
PCT/EP2001/008625 WO2002012899A2 (en) 2000-08-03 2001-07-26 Peptides presented by cells

Publications (2)

Publication Number Publication Date
DE60114018D1 true DE60114018D1 (de) 2006-02-23
DE60114018T2 DE60114018T2 (de) 2006-06-29

Family

ID=9896790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60114018T Expired - Lifetime DE60114018T2 (de) 2000-08-03 2001-07-26 Von zellen präsentierte peptide

Country Status (20)

Country Link
US (1) US20030171290A1 (de)
EP (1) EP1305343B1 (de)
JP (1) JP2004506202A (de)
KR (1) KR20030037272A (de)
CN (1) CN1511164A (de)
AT (1) ATE306498T1 (de)
AU (1) AU2001283958A1 (de)
BR (1) BR0112925A (de)
CA (1) CA2417767A1 (de)
CZ (1) CZ2003464A3 (de)
DE (1) DE60114018T2 (de)
GB (1) GB0018901D0 (de)
HU (1) HUP0301581A2 (de)
MX (1) MXPA03000901A (de)
NO (1) NO20030495L (de)
PL (1) PL358874A1 (de)
RU (1) RU2003105806A (de)
SK (1) SK1982003A3 (de)
WO (1) WO2002012899A2 (de)
ZA (1) ZA200301637B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513332A (ja) * 2000-09-18 2004-04-30 ジェンザイム、コーポレーション 質量分析法（ｍａｌｄｉ−ｔｏｆ）に基づいて抗体標的を同定するための方法
ATE386937T1 (de) * 2001-06-19 2008-03-15 Suntory Ltd Verfahren zur analyse eines in der zelle auftretenden proteins oder einer mit dem protein wechselwirkenden substanz
JP5097400B2 (ja) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． 複合ワクチン
AU2004283850C1 (en) 2003-10-16 2011-11-03 Amgen Research (Munich) Gmbh Multispecific deimmunized CD3-binders
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
EP2361930A3 (de) 2007-03-26 2011-10-26 Dako Denmark A/S Multimere von peptide-mhc komplexen und deren verwendung in borrelia infektionskrankheiten
EP2167536A1 (de) * 2007-07-03 2010-03-31 Dako Denmark A/S Mhc-multimere, verfahren zu ihrer herstellung, markierung und verwendung
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
AU2010314798B2 (en) 2009-11-05 2013-10-24 Teva Pharmaceuticals Australia Pty Ltd Treatment of cancer involving mutated KRAS or BRAF genes
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
MX2015015638A (es) * 2013-05-13 2016-10-28 Cellectis Metodos para diseñar celulas t altamente activas para inmunoterapia.
WO2018062973A1 (en) * 2016-09-30 2018-04-05 Cellex Life Sciences, Incorporated Compositions containing protein loaded exosome and methods for preparing and delivering the same
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
JP2002534959A (ja) * 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
WO2000064466A1 (en) * 1999-04-28 2000-11-02 Northwestern University Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
BR0112925A (pt) 2003-08-26
WO2002012899A3 (en) 2002-11-07
ZA200301637B (en) 2004-02-03
SK1982003A3 (en) 2003-08-05
AU2001283958A1 (en) 2002-02-18
WO2002012899A2 (en) 2002-02-14
RU2003105806A (ru) 2004-07-20
DE60114018T2 (de) 2006-06-29
MXPA03000901A (es) 2003-06-24
KR20030037272A (ko) 2003-05-12
NO20030495D0 (no) 2003-01-31
GB0018901D0 (en) 2000-09-20
HUP0301581A2 (hu) 2003-08-28
CZ2003464A3 (cs) 2003-06-18
JP2004506202A (ja) 2004-02-26
CN1511164A (zh) 2004-07-07
NO20030495L (no) 2003-01-31
EP1305343B1 (de) 2005-10-12
CA2417767A1 (en) 2002-02-14
US20030171290A1 (en) 2003-09-11
ATE306498T1 (de) 2005-10-15
EP1305343A2 (de) 2003-05-02
PL358874A1 (en) 2004-08-23

Similar Documents

Publication Publication Date Title
DE60114018D1 (de) Von zellen präsentierte peptide
Qin et al. Identification and characterization of posttranslational modifications of proteins by MALDI ion trap mass spectrometry
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1111006T1 (el) Εκριμματαση ασθενειας alzheimer
BR0211200A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
WO2006069203A3 (en) Methods for proteomic profiling using non-natural amino acids
NO331199B1 (no) Fremgangsmåter for fremvisning av (poly)peptider/proteiner på bakteriofagpartikler via disulfid bindinger, nukleinsyresekvens, vektor, vertscelle, modifiserte varianter av proteiner, bakteriofagpartikkel og variert samling av bakteriofagpartikler.
WO2002002783A3 (en) Expression vectors
WO2004024750A3 (en) Cd44-binding ligands
HUP0100697A2 (hu) Szilárdfázisú vizsgálatokhoz használható hegyek és alkalmazásuk
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
WO2000043493A8 (en) Metalloproteinase adam 22
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
WO2001053531A3 (en) Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells
ATE356207T1 (de) Humanes btrcp protein
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
PL374550A1 (en) Il-17 like molecules and uses thereof
SE9701228D0 (sv) Rekombinanta protein-C-och protein-S-varianter
WO2004050870A3 (en) Genetic switches for the detection of fusion proteins
BRPI0308978B8 (pt) fragmentos de peptídeos, e, composições imunogênicas
WO2004111086A3 (fr) ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
WO2003099209A3 (en) Compositions and methods for screening and identifying anti-hcv agents
ATE260339T1 (de) Antikörper gegen menschliches restrictin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition